PSA screening benefits at-risk men

Regular prostate specific antigen (PSA) screening may lead to earlier detection of prostate cancer in men whose genes put them at a higher risk, research suggests.

Coloured axial MRI scan of a patient with prostate cancer (Photograph: SPL)
Coloured axial MRI scan of a patient with prostate cancer (Photograph: SPL)

A study published in the British Journal of Urology International showed PSA testing predicted prostate cancer more effectively in men with high-risk BRCA mutations than in the general population.

There is currently no national screening programme for prostate cancer due to a lack of evidence for the benefit of PSA testing.

Mutations in genes BRCA1 and BRCA2 increase the risk of prostate cancer by up to seven- and two-fold respectively.

Researchers analysed data from 300 men aged 40-69 involved in the IMPACT trial.

A total of 205 men with BRCA1 or BRCA2 mutations and 95 non-carriers were offered annual PSA testing. Of these, 24 who had elevated PSA levels were given a follow-up biopsy.

The tests revealed that a higher proportion of mutation carriers had prostate cancer than non-carriers, with diagnosis rates of 3.9% cent and 2.1% respectively.

This translates to a predictive value of 48% for those with the mutations, compared with 24% among non-carriers.

The UK National Screening Committee will issue its next review of the evidence in March 2011.


Stephen Robinson

Stephen Robinson recommends

MIMS Oncology

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in